Trial Profile

ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jan 2026 Results published in the Nature Medicine and the Journal of Infectious Diseases.
12 Oct 2023 According to a Seres Therapeutics media release, results from post-hoc analysis of the ECOSPOR III and ECOSPOR IV Phase 3 studies will be presented at ID Week 2023
17 Jun 2023 According to a Seres Therapeutics media release, results from post-hoc analysis of the ECOSPOR III and ECOSPOR IV Phase 3 studies was featured as a late-breaker Emerging Science presentation at American Society of Microbiology (ASM) Microbe 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com